biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA
MAIA Biotechnology
Makai Biotechnology is a biotech organization headquartered in honolulu, USA. It trades on NYSE under ticker MAIA. Primary therapeutic focus areas include Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non
honolulu, USA HQ
2013 Founded
5 Employees
Public company Type
MAIA · NYSE Ticker
Company details
- Status
- Public
- HQ
- honolulu, USA
- Founded
- 2013
- Employees
- 5
- Programs
- 8
- Drugs
- 19
- Patents
- 10
6-Thio-2'-Deoxyguanosine
Phase 3 · small molecule · Carcinoma, Non-Small-Cell Lung
6-Thio-2'-Deoxyguanosine for Carcinoma, Non-Small-Cell Lung is a Phase 3 program (small_molecule) at MAIA Biotechnology with 2 ClinicalTrials.gov record(s).
Internal code THIO-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MAIA Biotechnology
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Carcinoma, Non-Small-Cell Lung
- Status
- active
- Trials
- 2